Akoya Biosciences Inc expected to post a loss of 29 cents a share - Earnings Preview

Akoya Biosciences

11/05/2024 24:35

* Akoya Biosciences Inc  AKYA.OQ   AKYA.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 13 for
the period ending March 31 2024
    * The Marlborough Massachusetts-based  company is expected
to
report a 13.4% increase in revenue to $24.281 million from
$21.41 million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Akoya Biosciences Inc is
for a
loss of 29 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.5%
in the last three months. ​
    * Wall Street's median 12-month price target for Akoya
Biosciences
Inc is $8.50​, above​ its last closing price of $4.27. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.27       -0.27      -0.22     Beat    18.1
 Sep. 30 0001  -0.36       -0.37      -0.26     Beat    28.9
 Jun. 30 2023  -0.43       -0.44      -0.46     Missed  -3.9​
 Mar. 31 2023  -0.50       -0.48      -0.49     Missed  -1.5
 ​​Dec.        -0.44       -0.43      -0.50     Missed  -16.3
 31 2022                                                
 Jan. 1 0001   -0.49       -0.44      -0.47     Missed  -6.8​
 Jun. 30 2022  -0.39       -0.37      -0.47     Missed  -26.3
 Mar. 31 2022  -0.40       -0.39      -0.44     Missed  -13.5
 This summary was machine generated May 10 at 23:35 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)